

**TORREYA:**

A Leading Global Advisor in the Generic Pharmaceuticals Sector

Torreyas Has Deep Advisory Experience in Generic Pharmaceuticals

CAPABILITIES	HIGHLIGHTS
<ul style="list-style-type: none"> <li>M&amp;A transactions                             <ul style="list-style-type: none"> <li>Corporate-level</li> <li>Asset-level</li> </ul> </li> <li>Advice on sale and purchase of manufacturing facilities</li> <li>Financing                             <ul style="list-style-type: none"> <li>Debt</li> <li>Growth equity</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Most active advisor in generic pharmaceuticals sector<sup>1</sup></li> <li>Globally active across generics sector in North America, Asia, and Europe</li> <li>Industry-leading team of eight professionals, with over 100 years of combined experience, including former heads of business development at Sandoz, Teva, and Cambrex</li> <li>Access to wide range of deal flow—largest players to small, entrepreneurial companies</li> </ul>

REPRESENTATIVE GENERIC PHARMACEUTICALS TRANSACTIONS SINCE 2015

Nearly \$4 Billion in Generic Deals Closed Since Torreyas's Inception

 <p>Divestiture of rare disease drug generic</p> <p>August 2018</p>	 <p>and affiliate Wintac, Limited acquired by</p>  <p><b>\$190 million</b> Announced April 2018</p>	 <p>Sale to</p>  <p>January 2018</p>	 <p>Sale of Majority Equity Stake to</p>  <p>December 2017</p>
 <p>Sale of generics portfolio to</p>  <p><b>\$18 million</b> August 2017</p>	 <p>Acquisition of generics business of</p>  <p><b>\$1.05 billion</b> June 2017</p>	 <p>Sale of India women's health business to</p>  <p>April 2017</p>	 <p>Sale of Intrathecal business to</p>  <p><b>\$203 million</b> March 2017</p>
 <p>Sale of equity stake to</p>  <p><b>\$33 million</b> November 2016</p>	 <p>Company sale to</p>  <p><b>\$100+ million</b> December 2015</p>	 <p>Acquisition of</p>  <p><b>CAD \$47 million</b> October 2015</p>	 <p>Sale of ANDA portfolio to</p>  <p><b>\$25 million + profit share</b> July 2015</p>

TORREYA.COM  
NEW YORK | LONDON | MUMBAI

For more information, please contact +1 212.257.5801

Securities offered in the United States are offered through Torreyas Capital LLC, Member FINRA/SIPC.

In Europe, such services are offered through Torreyas Partners (Europe) LLP, which is authorised and regulated by the UK Financial Conduct Authority.

<sup>1</sup> Capital IQ and Torreyas calculations: 2016 – 2017